• Chimeric Anti-CD14 IGG2/4 Hybrid Antibodies for Therapeutic Intervention in Pig and Human Models of Inflammation 

      Lau, Corinna; Gunnarsen, Kristin Støen; Høydahl, Lene Støkken; Andersen, Jan Terje; Berntzen, Gøril; Pharo, Anne Margrethe; Lindstad, Julie Katrine; Ludviksen, Judith K; Brekke, Ole Lars; Barratt-Due, Andreas; Nielsen, Erik Waage; Stokes, Christopher R.; Espevik, Terje; Sandlie, Inger; Mollnes, Tom Eirik (Journal article; Peer reviewed, 2013)
      CD14 is a key recognition molecule of innate immune responses, interacting with several TLRs. TLR signaling cross-talks extensively with the complement system, and combined CD14 and complement inhibition has been proved ...
    • Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn 

      Hallstensen, Randi; Bergseth, Grete; Foss, Stian; Jæger, Steinar; Gedde-Dahl, Thobias; Holt, jan; Christiansen, Dorte; Lau, Corinna; Brekke, Ole Lars; Armstrong, Elina; Stefanovic, Vedran; Andersen, Jan Terje; Sandlie, Inger; Mollnes, Tom Eirik (Journal article; Peer reviewed, 2015)
      Eculizumab is a humanized IgG2/4 chimeric anti-complement C5 antibody used to treat patients with paroxysmal nocturnal hemoglobinuria (PNH) or atypical hemolytic uremic syndrome. The aim of this study was to evaluate whether ...
    • NHDL, a recombinant VL/VH hybrid antibody control for IgG2/4 antibodies. 

      Lau, Corinna; McAdam, MB; Bergseth, G; Grevys, Algirdas; Bruun, JA; Ludviksen, Judith K; Fure, Hilde; Espevik, Terje; Moen, A; Andersen, Jan Terje; Mollnes, Tom Eirik (Journal article; Peer reviewed, 2020)
      The mechanism of action of recombinant IgG2/4 antibodies involves blocking of their target without the induction of effector functions. Examples are eculizumab (Soliris®), which is used clinically to block complement factor ...